 I. Characterize the pharmacokinetic PK profile of VX-970. II. Assess for potential drug-drug interaction between VX-970 and aprepitant. III. To observe and record anti-tumor activity. IV. To assess the rate of complete metabolic response CMR at 12 weeks post completion of chemoradiation using 18 fluorodeoxyglucose FDG positron emission tomography PET scans. 